We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.55% | 39.79 | 40.005 | 39.675 | 39.97 | 853,833 | 15:38:55 |
From Jul 2021 to Jul 2024
By Sabela Ojea
GlaxoSmithKline PLC said Tuesday that its Apretude drug, which reduces the risk of HIV acquisition, has been approved by the U.S. Food and Drug Administration.
The British pharma major said that Apretude was developed by ViiV Healthcare, the specialist HIV company majority owned by GSK.
"Apretude is the first and only pre-exposure prophylaxis option to reduce the risk of sexually acquired HIV," the FTSE 100 listed company said.
The drug was approved for use by adults and adolescents weighing at least 35 kilograms, the company said.
"With Apretude, people can reduce the risk of acquiring HIV with as few as six injections a year," said Deborah Waterhouse, Chief Executive of ViiV Healthcare.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 21, 2021 02:33 ET (07:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
